Cytokinetics (CYTK) Short term Debt (2011 - 2026)
Cytokinetics (CYTK) posted quarterly Short term Debt of $44.8 million for Q1 2026, up 245.74% year-over-year from $13.0 million in Q1 2025, and up 8.81% quarter-over-quarter from $41.2 million in Q4 2025.
Cytokinetics (CYTK) Short term Debt (2011 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Short term Debt for 12 consecutive years, with $44.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt rose 245.74% year-over-year to $44.8 million; the TTM figure through Mar 2026 stood at $44.8 million (up 245.74% YoY), while the FY2025 annual figure was $41.2 million, up 257.47% from the prior year.
- Short term Debt climbed to $44.8 million in Q1 2026 per CYTK's latest filing, from $41.2 million in the prior quarter.
- Across five years, Short term Debt topped out at $44.8 million in Q1 2026 and bottomed at $958000.0 in Q4 2022.
- Historically, Short term Debt has averaged $17.1 million across 5 years, with a median of $11.5 million in 2024.
- Annual changes were most pronounced in 2023 — Short term Debt surged 952.19% — and 2025, when it gained 12.5%.
- Cytokinetics' Short term Debt stood at $958000.0 in 2022, then soared by 952.19% to $10.1 million in 2023, then increased by 14.29% to $11.5 million in 2024, then jumped by 257.47% to $41.2 million in 2025, then rose by 8.81% to $44.8 million in 2026.
- Business Quant data shows CYTK's Short term Debt at $44.8 million in Q1 2026, $41.2 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.36 Mn |
| Mar 31, 2026 | 44.81 Mn |
| Dec 31, 2025 | 41.18 Mn |
| Sep 30, 2025 | 17.28 Mn |
| Jun 30, 2025 | 14.40 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 11.52 Mn |
| Sep 30, 2024 | 11.52 Mn |
| Jun 30, 2024 | 11.52 Mn |
| Mar 31, 2024 | 11.52 Mn |
| Dec 31, 2023 | 10.08 Mn |
| Dec 31, 2022 | 958,000.00 |
| Sep 30, 2021 | 16.88 Mn |
| Jun 30, 2021 | 11.25 Mn |
| Mar 31, 2021 | 5.63 Mn |
| Mar 31, 2019 | 6.21 Mn |
| Dec 31, 2018 | 2.61 Mn |
| Sep 30, 2018 | 3.78 Mn |
| Jun 30, 2018 | 1.70 Mn |
| Sep 30, 2017 | 9.83 Mn |